9.8: Example - Building a shared response through ACTIV

Quality and Regulatory Compliance in Bioscience · LibreTexts

0%

Contents

    Text

    Size
    100%
    Theme
    Typeface
    Line length
    Spacing

    Read aloud

    How

    Speed: 1×
    Light up
    Highlight

    Symbols: Mulberry Symbols, © 2018–2026 Steve Lee, CC BY-SA 4.0 (licence, the set), the site's own copies.

    From LibreTexts, under CC BY-SA 4.0, as the source states it; its equations are written in TeX, which the PDF shows typeset. This page at LibreTexts.

    9.8: Example - Building a shared response through ACTIV

    ACTIV_ From purpose to organized work.pngNIH records from 2020 describe a collaboration moving from an announced purpose to organized work. This historical account follows those events without invented dialogue or private thoughts. The comparison with a local quality team is a teaching interpretation.

    On April 17, 2020, NIH and the Foundation for the NIH announced a partnership to speed COVID-19 treatment and vaccine research. It included 16 biopharmaceutical companies and public agencies, including CDC, FDA, and the European Medicines Agency. Its name was Accelerating COVID-19 Therapeutic Interventions and Vaccines, or ACTIV. The announcement set out a framework for prioritizing candidates, streamlining trials, and sharing research assets. 

    The broad assignment needed a division of work. A later NIH account described four working groups: Preclinical, Therapeutics Clinical, Clinical Trial Capacity, and Vaccines. Each had an NIH co-chair and an industry co-chair. The groups gave separate areas of work named leadership while connecting them to the larger partnership. 

    The same account reported a resource pledge: industry partners would contribute clinical-trial capacity and support promising candidates regardless of their developer. The pledge described support the collaboration intended to provide. It did not measure how much each partner later contributed or prove that every resource need had been met. 

    By July 2, 2020, official testimony hosted by NIH described an output beyond the partnership announcement. ACTIV’s Therapeutics Clinical Working Group had developed and openly shared master protocols with agreed endpoints, sampling, and analysis. A master protocol is an overarching research plan for evaluating multiple interventions using shared design features. These documents provided a basis for coordinated research; they were not results showing a treatment worked. 

    For a student studying team launch, the sequence is useful: a stated purpose, named work areas, shared leadership, resource commitments, and an identifiable output. That sequence is a teaching interpretation of the documented events. The sources document early organization and outputs, rather than an internal charter, team-development stages, or the effectiveness of a particular treatment.

    A small laboratory team operates on a different scale, but it faces related questions. Who is responsible for each area of work? What will partners contribute? What output should exist by the next checkpoint? Clear answers help a team move from agreement in principle to coordinated action.


    This page titled 9.8: Example - Building a shared response through ACTIV was last modified on Sun, 08 Nov 2026 11:51:22 GMT and is shared under a CC BY-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.